038290:KOSDAQ
Macrogen Inc
11Â 910,00Â â‚©
arrow_downward
-0,75%(-90,00) 1K
21-sen, 15:30:30 (GMT+9) · KRW
search
Barcha belgilar
1K
5K
1O
6O
YBB
1Y
5Y
MAKS
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_auto038290 tikeri uchun statistika yaratilmoqda...
Ochish
12Â 100Â â‚©
Yuqori
12Â 100Â â‚©
Past
11Â 750Â â‚©
Bozor kapitali
129,12Â mlrd
Oʻrtacha hajm
31,84Â ming
Hajmi
9,49Â ming
Dividend
4,20%
Choraklik dividendlar
125Â â‚©
Eks-dividend sanasi
27-dek, 2024
P/E koeffitsiyenti
12,49
52 haftalik eng yuqori
20Â 900Â â‚©
52 haftalik eng past
10Â 440Â â‚©
Aksiya boʻyicha daromad
953Â â‚©
Muomaladagi aksiyalar
10,84Â mln
Xodimlar soni
473
Ochish
12Â 100Â â‚©
Yuqori
12Â 100Â â‚©
Past
11Â 750Â â‚©
Bozor kapitali
129,12Â mlrd
Oʻrtacha hajm
31,84Â ming
Hajmi
9,49Â ming
Dividend
4,20%
Choraklik dividendlar
125Â â‚©
Eks-dividend sanasi
27-dek, 2024
P/E koeffitsiyenti
12,49
52 haftalik eng yuqori
20Â 900Â â‚©
52 haftalik eng past
10Â 440Â â‚©
Aksiya boʻyicha daromad
953Â â‚©
Muomaladagi aksiyalar
10,84Â mln
Xodimlar soni
473
Profil
Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia
Macrogen Inc haqida